{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:45:06Z","timestamp":1793432706374,"version":"4.5.0"},"reference-count":43,"publisher":"The Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Context: Despite recognition that androgen deficiency in men should be defined according to biochemical and clinical criteria, most prevalence estimates are based on low testosterone levels alone.<\/jats:p>\n                  <jats:p>Objective: The objective of this study was to examine the association between symptoms of androgen deficiency and low total and calculated free testosterone levels and estimate the prevalence of symptomatic androgen deficiency in men.<\/jats:p>\n                  <jats:p>Design: This study was a population-based, observational survey.<\/jats:p>\n                  <jats:p>Participants: A total of 1475 Black, Hispanic, and white men, between the ages of 30\u201379 yr, with complete data on testosterone, SHBG, and symptoms of androgen deficiency, and who are not taking medications that impact sex steroid levels were randomly selected from the Boston Area Community Health Survey.<\/jats:p>\n                  <jats:p>Outcome: Outcomes were measured as symptomatic androgen deficiency, defined as low total (&amp;lt;300 ng\/dl) and free (&amp;lt;5 ng\/dl) testosterone plus presence of low libido, erectile dysfunction, osteoporosis or fracture, or two or more of following symptoms: sleep disturbance, depressed mood, lethargy, or diminished physical performance.<\/jats:p>\n                  <jats:p>Results: Mean age of the sample was 47.3 \u00b1 12.5 yr. Approximately 24% of subjects had total testosterone less than 300 ng\/dl, and 11% of subjects had free testosterone less than 5 ng\/dl. Prevalence of symptoms were as follows: low libido (12%), erectile dysfunction (16%), osteoporosis\/fracture (1%), and two or more of the nonspecific symptoms (20%). Low testosterone levels were associated with symptoms, but many men with low testosterone levels were asymptomatic (e.g. in men 50+ yr, 47.6%). Crude prevalence of symptomatic androgen deficiency was 5.6% (95% confidence interval: 3.6%, 8.6%), and was not significantly related to race and ethnic group. Prevalence was low in men less than 70 yr (3.1\u20137.0%) and increased markedly with age to 18.4% among 70 yr olds. Projection of these estimates to the year 2025 suggests that there will be as many as 6.5 million American men ages 30\u201379 yr with symptomatic androgen deficiency, an increase of 38% from 2000 population estimates.<\/jats:p>\n                  <jats:p>Conclusions: Prevalence of symptomatic androgen deficiency in men 30 and 79 yr of age is 5.6% and increases substantially with age. The aging of the U.S. male population will cause a large increase in the burden of symptomatic androgen deficiency. Future work should address the clinical significance of low testosterone levels in asymptomatic men.<\/jats:p>","DOI":"10.1210\/jc.2007-1245","type":"journal-article","created":{"date-parts":[[2007,8,14]],"date-time":"2007-08-14T20:31:25Z","timestamp":1187123485000},"page":"4241-4247","source":"Crossref","is-referenced-by-count":582,"title":["Prevalence of Symptomatic Androgen Deficiency in Men"],"prefix":"10.1210","volume":"92","author":[{"given":"Andre B.","family":"Araujo","sequence":"first","affiliation":[{"name":"New England Research Institutes, Inc. (A.B.A., G.R.E., V.K., A.B.O., T.G.T., J.B.M.), Watertown, Massachusetts 02472"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen R.","family":"Esche","sequence":"first","affiliation":[{"name":"New England Research Institutes, Inc. (A.B.A., G.R.E., V.K., A.B.O., T.G.T., J.B.M.), Watertown, Massachusetts 02472"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varant","family":"Kupelian","sequence":"first","affiliation":[{"name":"New England Research Institutes, Inc. (A.B.A., G.R.E., V.K., A.B.O., T.G.T., J.B.M.), Watertown, Massachusetts 02472"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy B.","family":"O\u2019Donnell","sequence":"first","affiliation":[{"name":"New England Research Institutes, Inc. (A.B.A., G.R.E., V.K., A.B.O., T.G.T., J.B.M.), Watertown, Massachusetts 02472"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Travison","sequence":"first","affiliation":[{"name":"New England Research Institutes, Inc. (A.B.A., G.R.E., V.K., A.B.O., T.G.T., J.B.M.), Watertown, Massachusetts 02472"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Williams","sequence":"first","affiliation":[{"name":"GlaxoSmithKline Research and Development (R.E.W., R.V.C.), Research Triangle Park, North Carolina 27709"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard V.","family":"Clark","sequence":"first","affiliation":[{"name":"GlaxoSmithKline Research and Development (R.E.W., R.V.C.), Research Triangle Park, North Carolina 27709"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"McKinlay","sequence":"first","affiliation":[{"name":"New England Research Institutes, Inc. (A.B.A., G.R.E., V.K., A.B.O., T.G.T., J.B.M.), Watertown, Massachusetts 02472"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071613103407200_R1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1210\/jcem.87.2.8201","article-title":"Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study.","volume":"87","author":"Feldman","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613103407200_R2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/jcem.86.2.7219","article-title":"Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.","volume":"86","author":"Harman","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613103407200_R3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0950-351X(97)80302-3","article-title":"Declining gonadal function in elderly men.","volume":"11","author":"Kaufman","year":"1997","journal-title":"Baillieres Clin Endocrinol Metab"},{"key":"2020071613103407200_R4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/oxfordjournals.aje.a009326","article-title":"Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants.","volume":"146","author":"Zmuda","year":"1997","journal-title":"Am J Epidemiol"},{"key":"2020071613103407200_R5","volume-title":"Testosterone and aging: clinical research directions","author":"Liverman","year":"2004"},{"key":"2020071613103407200_R6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1210\/er.2004-0013","article-title":"The decline of androgen levels in elderly men and its clinical and therapeutic implications.","volume":"26","author":"Kaufman","year":"2005","journal-title":"Endocr Rev"},{"key":"2020071613103407200_R7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2265.2006.02560.x","article-title":"Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study.","volume":"65","author":"Derby","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613103407200_R8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1530\/eje.1.02241","article-title":"The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study.","volume":"155","author":"Mohr","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"2020071613103407200_R9","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2337\/diacare.27.5.1036","article-title":"Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.","volume":"27","author":"Laaksonen","year":"2004","journal-title":"Diabetes Care"},{"key":"2020071613103407200_R10","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2337\/diacare.23.4.490","article-title":"Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study.","volume":"23","author":"Stellato","year":"2000","journal-title":"Diabetes Care"},{"key":"2020071613103407200_R11","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1210\/jc.2005-1326","article-title":"Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men.","volume":"91","author":"Kupelian","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613103407200_R12","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2005-1830","article-title":"Testosterone and estradiol among older men.","volume":"91","author":"Orwoll","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613103407200_R13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.5694\/j.1326-5377.2004.tb06060.x","article-title":"11: Androgen deficiency and replacement therapy in men.","volume":"180","author":"Handelsman","year":"2004","journal-title":"Med J Aust"},{"key":"2020071613103407200_R14","doi-asserted-by":"crossref","first-page":"M76","DOI":"10.1093\/gerona\/57.2.M76","article-title":"Andropause: clinical implications of the decline in serum testosterone levels with aging in men","volume":"57","author":"Matsumoto","year":"2002","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2020071613103407200_R15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2605.2005.00553.x","article-title":"Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations.","volume":"28","author":"Nieschlag","year":"2005","journal-title":"Int J Androl"},{"key":"2020071613103407200_R16","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1210\/jc.2005-2847","article-title":"Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline.","volume":"91","author":"Bhasin","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613103407200_R17","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1210\/jc.2003-031719","article-title":"Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study.","volume":"89","author":"Araujo","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613103407200_R18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1210\/jc.2006-1375","article-title":"A population-level decline in serum testosterone levels in American men.","volume":"92","author":"Travison","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613103407200_R19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.eururo.2007.03.013","article-title":"Measuring the urologic iceberg: design and implementation of the Boston Area Community Health (BACH) Survey.","volume":"52","author":"McKinlay","year":"2007","journal-title":"Eur Urol"},{"key":"2020071613103407200_R20","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1210\/jcem-56-6-1278","article-title":"Loss of circadian rhythmicity in blood testosterone levels with aging in normal men.","volume":"56","author":"Bremner","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613103407200_R21","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1046\/j.1365-2265.2003.01772.x","article-title":"Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men.","volume":"58","author":"Diver","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613103407200_R22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0895-4356(95)00569-2","article-title":"Does collecting repeated blood samples from each subject improve the precision of estimated steroid hormone levels?","volume":"49","author":"Brambilla","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"2020071613103407200_R23","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0022-4731(82)90038-3","article-title":"Calculation of free and bound fractions of testosterone and estradiol-17\u03b2 to human plasma proteins at body temperature.","volume":"16","author":"So\u0308dergard","year":"1982","journal-title":"J Steroid Biochem"},{"key":"2020071613103407200_R24","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1210\/jcem.84.10.6079","article-title":"A critical evaluation of simple methods for the estimation of free testosterone in serum.","volume":"84","author":"Vermeulen","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613103407200_R25","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction.","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"key":"2020071613103407200_R26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity.","volume":"34","author":"Ware Jr","year":"1996","journal-title":"Med Care"},{"key":"2020071613103407200_R27","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1210\/jc.2006-0037","article-title":"Serum androgen levels in black, Hispanic, and white men.","volume":"91","author":"Litman","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613103407200_R28","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1210\/jc.2006-2799","article-title":"Commentary: Guideline for male testosterone therapy: a European perspective.","volume":"92","author":"Wu","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613103407200_R29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/13685539909003173","article-title":"A new \u201cAging Male\u2019s Symptoms\u201d (AMS) rating scale.","volume":"2","author":"Heinemann","year":"1999","journal-title":"Aging Male"},{"key":"2020071613103407200_R30","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1053\/meta.2000.8625","article-title":"Validation of a screening questionnaire for androgen deficiency in aging males.","volume":"49","author":"Morley","year":"2000","journal-title":"Metabolism"},{"key":"2020071613103407200_R31","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1046\/j.1365-2265.2000.01152.x","article-title":"Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men.","volume":"53","author":"Smith","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613103407200_R32","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1210\/jc.2006-0401","article-title":"Association of specific symptoms and metabolic risks with serum testosterone in older men.","volume":"91","author":"Zitzmann","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613103407200_R33","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1210\/jc.2005-2508","article-title":"The relationship between libido and testosterone levels in aging men.","volume":"91","author":"Travison","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613103407200_R34","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1210\/jc.2004-0143","article-title":"Blood testosterone threshold for androgen deficiency symptoms.","volume":"89","author":"Kelleher","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613103407200_R35","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1439-0272.2005.00692.x","article-title":"The androgen receptor CAG repeat polymorphism","volume":"37","author":"Zitzmann","year":"2005","journal-title":"Andrologia"},{"key":"2020071613103407200_R36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1046\/j.1365-2605.2003.00393.x","article-title":"The CAG repeat polymorphism within the androgen receptor gene and maleness.","volume":"26","author":"Zitzmann","year":"2003","journal-title":"Int J Androl"},{"key":"2020071613103407200_R37","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.metabol.2006.06.019","volume":"55","author":"Wong","journal-title":"Metabolism"},{"key":"2020071613103407200_R38","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2337\/dc06-1426","article-title":"Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity.","volume":"30","author":"Kapoor","year":"2007","journal-title":"Diabetes Care"},{"key":"2020071613103407200_R39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2605.2002.00356.x","article-title":"Impact of obesity on hypogonadism in the andropause.","volume":"25","author":"Tan","year":"2002","journal-title":"Int J Androl"},{"key":"2020071613103407200_R40","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1373\/49.8.1381","article-title":"Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children.","volume":"49","author":"Taieb","year":"2003","journal-title":"Clin Chem"},{"key":"2020071613103407200_R41","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1210\/jc.2003-031287","article-title":"Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry.","volume":"89","author":"Wang","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613103407200_R42","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00198-006-0321-9","article-title":"Race\/ethnic differences in bone mineral density in men.","volume":"18","author":"Araujo","year":"2007","journal-title":"Osteoporos Int"},{"key":"2020071613103407200_R43","volume-title":"Generalized additive models","author":"Hastie","year":"1990"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/11\/4241\/9052280\/jcem4241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/11\/4241\/9052280\/jcem4241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T19:15:04Z","timestamp":1594926904000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/92\/11\/4241\/2598366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,1]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2007-1245","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1091822.545132","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,1]]}}}